Charles River Laboratories
Charles River Laboratories is a leading global contract research organization (CRO) renowned for its extensive contributions to oncology research, particularly through its robust portfolio of Patient-Derived Xenograft (PDX) models. The company maintains one of the largest and most well-characterized collections in the industry, comprising over 1,700 models established through international collaborations with major hospitals. Charles River’s PDX models are utilized across all therapeutic modalities, from small molecules to cell therapy, and are designed to retain the biological integrity and clinical relevance of the original human tumor. They offer comprehensive services including various in vivo models (subcutaneous, orthotopic, disseminated, and humanized mouse models), alongside advanced in vitro screening assays and innovative in silico tools, such as AI-enabled drug discovery platforms and virtual control groups. Notably, their PDX models cover a wide range of cancer types, including high-need areas like AML, ovarian, and pediatric tumors. The recent acquisition of Oncodesign further cemented Charles River’s position as a key global PDX provider, focusing on delivering high-quality, molecularly characterized models essential for accelerating preclinical drug development and advancing personalized medicine.
Latest Market Research Report on Patient-Derived Xenograft Model Download PDF Brochure Now
Crown Bioscience
Crown Bioscience, a global drug discovery and development services company, is recognized as a dominant player in the PDX market, primarily due to possessing the world’s largest collection of highly-characterized PDX models, exceeding 2,500 across more than 30 indications. The company specializes in offering highly translational preclinical models crucial for efficacy screening and cancer drug development. A core strength is their expertise in conducting PDX Mouse Clinical Trials (MCTs), which replicate clinical trial conditions preclinically to enhance success rates and reduce drug attrition. To ensure model integrity, Crown Bioscience employs a patented Next-Generation Sequencing Quality Control (NGS-QC) method to guard against contamination and misidentification. Their platforms are designed to provide rapid results, utilizing over 500 live PDX models for fast-track services. Crown Bioscience supports researchers with end-to-end services, including bioinformatics support, advanced biomarker testing, and offering specialized models like PDX-Derived Cell Lines and Liquid Tumor PDX models, positioning them as a critical partner for translational oncology research.
Champions Oncology
Champions Oncology is a technology-enabled oncology CRO that provides a robust platform focused entirely on Patient-Derived Xenograft solutions to accelerate cancer drug development. The company has established one of the industry’s largest and most clinically relevant banks of solid tumor PDX models, which are extensively annotated and deeply characterized. Champions Oncology emphasizes the high translational power of its models, which are instrumental in conducting pharmacology studies to gain actionable insights into therapeutic efficacy and drug resistance. Their services encompass the entire PDX study lifecycle, from initial consultation and model selection to meticulous study design, implementation, comprehensive data analysis, and detailed reporting. By providing high-quality, pretreated PDX models and a commitment to high standards, Champions Oncology helps pharmaceutical and biotech sponsors achieve more accurate and meaningful results in their preclinical studies, driving forward the development of novel drug candidates and personalized treatment strategies.
The Jackson Laboratory (JAX)
The Jackson Laboratory (JAX) is an independent, non-profit biomedical research institution known globally as a leader in mammalian genetics and human disease models, making it a foundational resource in the Patient-Derived Xenograft (PDX) market. JAX supplies a comprehensive array of genetically defined mice, which are essential for the successful engraftment and growth of human tumors required in PDX studies. They contribute significantly to pan-cancer research efforts through various consortiums and their own repository, offering highly reliable and validated PDX models. While they may not function as a full-service CRO in the same manner as others, their primary role is providing the critical biological infrastructure—specifically the immunodeficient mouse strains and established PDX lines—that enable preclinical oncology research worldwide. Their focus on genetic characterization and quality control makes JAX a trusted source for researchers and commercial partners seeking standardized, high-quality models to study tumor biology, drug resistance, and therapeutic response.
XenoSTART
XenoSTART serves as the preclinical division specializing in oncology drug development, known for offering an extensive collection of high-quality Patient-Derived Xenograft (PDX) models. The company differentiates itself by leveraging a global network of community-based oncology centers to meticulously source its models, resulting in a collection of over 2,500 models—one of the largest in the industry. XenoSTART operates a streamlined “Clinic-to-Bench” pipeline, which is crucial for delivering clinically relevant PDX models that capture real-world patient data. This pipeline is informed directly by insights from its clinical counterpart, The START Center for Cancer Research, the world’s largest early-phase oncology trial site organization. This integration of clinical and preclinical expertise allows XenoSTART to optimize tissue sourcing and PDX study design, ensuring high predictive value for drug development programs and accelerating the advancement of innovative oncology treatments.
WuXi AppTec
WuXi AppTec is a global contract research, development, and manufacturing organization (CRDMO) that plays a critical role in the Patient-Derived Xenograft (PDX) market by offering comprehensive preclinical oncology services. Leveraging its extensive global platform, the company assists pharmaceutical, biotech, and medical device companies throughout the entire drug discovery and development pipeline. WuXi AppTec utilizes PDX models as a superior translational tool for testing the efficacy, pharmacokinetics, and pharmacodynamics of novel cancer therapeutics. They manage and characterize PDX models covering a broad spectrum of cancer types, supporting researchers in identifying potential biomarkers and optimizing dosing regimens. By providing integrated, high-quality PDX services alongside other necessary research services, WuXi AppTec enables clients to streamline complex preclinical workflows and accelerate the transition of promising drug candidates from the laboratory bench to clinical trials.
XenTech
XenTech is a specialized preclinical oncology CRO known for its expertise in developing and utilizing Patient-Derived Xenograft (PDX) models, particularly focusing on advancing research in immuno-oncology. The company provides models that are highly translational, allowing for accurate assessment of novel therapeutics and biomarker identification in a physiologically relevant context. XenTech is recognized for its capacity to generate and characterize models using advanced techniques. A significant development for the company is its strategic partnership with Transgene, aimed at commercializing novel PDX models integrated with a humanized mouse immune system platform. This collaboration is specifically designed to create advanced models capable of accurately predicting the efficacy of complex immuno-oncology agents, solidifying XenTech’s position as an innovative partner in next-generation cancer therapy development.
Noble Life Sciences
Noble Life Sciences is a contract research organization (CRO) dedicated to preclinical oncology research, with a strong focus on providing high-quality Patient-Derived Xenograft (PDX) models. The company highlights that their PDX models meticulously retain the heterogeneity, molecular characteristics, and the crucial tumor microenvironment of the original patient tumors, offering a highly predictive translational platform. Noble Life Sciences supports a comprehensive range of cancer studies, including models for colorectal, lung, breast, and other tumor types. They offer flexibility in implantation, including subcutaneous xenografts for rapid screening and orthotopic implantation for studies requiring a more physiologically relevant tumor microenvironment. Beyond model generation, Noble provides full-spectrum oncology CRO services, encompassing in vivo drug efficacy studies, advanced biomarker discovery using techniques like flow cytometry and IHC, and detailed PK/PD analysis, serving as a trusted partner for regulatory-compliant preclinical assessments.
InnoSer
InnoSer functions as a dedicated preclinical oncology CRO, specializing in providing clinically relevant Patient-Derived Xenograft (PDX) models to the biopharmaceutical industry. The company strongly recommends the adoption of PDX models—following initial cell line-derived studies—to obtain more translatable and clinically meaningful results in the complex field of anticancer therapy development. InnoSer emphasizes maintaining the representative nature of their models by strictly managing the propagation steps, ensuring they closely resemble the original patient tumor characteristics. They possess extensive experience in working with various highly immunodeficient mouse strains, such as NOD-SCID and NSG/NOG, which are necessary for successful human tumor engraftment. By offering flexible study start times and collaborating with clients on optimal study design, InnoSer strives to accelerate the pace of preclinical research and efficiently navigate the challenges of oncology drug development.
Abnova Corp.
Abnova Corp. is a global leader in providing biological research reagents and instruments, and is recognized as a key company contributing to the Patient-Derived Xenograft (PDX) Model market. While their core business is expansive, their involvement in PDX models centers around offering related tools, reagents, and research services essential for the establishment, characterization, and downstream analysis of these models. This includes kits and antibodies necessary for immunohistochemistry, gene expression analysis, and other validation techniques applied to PDX tissue. By supplying the critical components and research infrastructure, Abnova supports both commercial CROs and academic institutions in their utilization and research involving PDX technology, thereby facilitating its widespread application in oncology drug screening and translational studies globally.
Latest Market Research Report on Patient-Derived Xenograft Model Download PDF Brochure Now